ArticleNeurosurgical review2026
Strategy of adult thalamic glioma surgery: Thoughts and practices based on thalamic glioma classification.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Adult thalamic gliomas (ATGs) present a significant surgical challenge due to their deep location and proximity to critical brain structures. To standardize the surgical approaches, we proposed a novel anatomically-guided classification that divides thalamic gliomas into four distinct zones, each associated with specific surgical approaches. This retrospective study included 201 patients (median age 40 years) with WHO grade 2–4 thalamic gliomas treated at West China Hospital from 2012 to 2024. Utilizing two vertical lines transecting the internal capsule genu and the third ventricle midpoint, we categorized thalamic gliomas into Zone I (anterolateral), Zone II (posterolateral), Zone III (dorsomedial), and Zone IV (ventromedial). Survival analysis was performed using multivariable Cox regression with bidirectional stepwise selection, Kaplan–Meier analysis and log-rank testing. Intervariable associations were quantified using Cramer's V. Tumors invading multiple zones were the most frequent, representing 23.88% of cases, whereas only 1.98% involved both cerebral hemispheres. Supra-tentorial lateral approaches were most commonly employed (51.4%), and no patients required a supracerebellar infratentorial approach. Median overall survival was 10 months. After adjusting for molecular markers, adjuvant therapy and WHO grading, extent of resection (EOR) remained an independent prognostic factor (vs. gross total resection: subtotal HR = 1.62, p = 0.04; partial HR = 1.87, p < 0.001). Surgical approach significantly correlated with EOR in Zones I + II and II + III (p < 0.05), while Zones IV and III + IV demonstrated strong effect sizes (Cramer's V = 0.516 and 0.356, respectively), although these associations did not reach statistical significance. Maximal safe resection is a clinically justified first-line treatment for ATG patients. The transcallosal anterior approach is recommended for midline tumors located in Zones III, IV, or III + IV, particularly in cases involving obstructive hydrocephalus. For posterolateral tumors in Zones II and II + III, the approach should be determined by the direction of tumor extension. Nevertheless, further research with larger sample sizes is warranted to refine and optimize treatment strategies for thalamic gliomas. Clinical trial number: not applicable.
Indexed as
Identifiers
41609920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.